Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Resomelagon by SynAct Pharma for Rheumatoid Arthritis: Likelihood of Approval
Resomelagon is under clinical development by SynAct Pharma and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase...
Data Insights
Resomelagon by SynAct Pharma for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome: Likelihood of Approval
Resomelagon is under clinical development by SynAct Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute...